Table 3.

Univariable regression analyses for the association of the change in red blood cell potassium after each intervention

Variables	Difference in Change (95% CI)	P Value	Difference in Change (95% CI)	P Value
	Potassium Citrate without Lisinopril		Potassium Chloride without Lisinopril
	Δ RBC K+ (mmol) T0–T120
Age, yr	0.01 (−0.02 to 0.03)	0.54	0.01 (−0.1 to 0.03)	0.18
Sex, woman	−0.5 (−1.4 to 0.3)	0.18	0.3 (−0.4 to 0.9)	0.36
BMI, kg/m2	−0.03 (−0.13 to 0.08)	0.61	0.07 (−0.01 to 0.16)	0.08
24-h potassium excretion, mmol	0.01 (−0.01 to 0.02)	0.30	−0.00 (−0.01 to 0.01)	0.49
Baseline eGFR, ml/min per 1.73 m2	−0.01 (−0.03 to 0.01)	0.23	−0.01 (−0.03 to 0.01)	0.15
Baseline plasma potassium, mmol/L	0.4 (−2.2 to 3.1)	0.74	0.7 (−0.6 to 2.1)	0.26
Baseline venous pH	−15 (−24 to −4)	0.01	−2 (−12 to 9)	0.71
Baseline plasma bicarbonate, mmol/L	0.02 (−0.09 to 0.14)	0.67	0.02 (−0.11 to 0.15)	0.74
Baseline Ln plasma aldosterone, ng/L	−0.4 (−1.2 to 0.5)	0.38	−0.7 (−1.3 to −0.1)	0.02
Baseline Ln plasma renin, ng/L	−0.1 (−1.7 to 1.4)	0.87	−0.8 (−1.5 to 0.0)	0.06
	Potassium Citrate with Lisinopril		Potassium Chloride with Lisinopril
	Δ RBC K+ (mmol) T0–T120
Age, yr	−0.01 (−0.04 to 0.02)	0.51	0.00 (−0.02 to 0.03)	0.87
Sex, woman	0.8 (−0.2 to 1.7)	0.10	0.1 (−0.8 to 0.9)	0.89
BMI, kg/m2	−0.03 (−0.17 to 0.11)	0.69	0.01 (−0.09 to 0.11)	0.88
24-h potassium excretion, mmol	0.01 (−0.01 to 0.02)	0.27	0.00 (−0.01 to 0.01)	0.98
Baseline eGFR, ml/min per 1.73 m2	0.02 (−0.01 to 0.05)	0.11	0.00 (−0.02 to 0.03)	0.70
Baseline plasma potassium, mmol/L	−1.4 (−3.0 to 0.3)	0.09	−0.5 (−2.7 to 1.8)	0.65
Baseline venous pH	−4 (−23 to 14)	0.62	−7 (−19 to 5)	0.26
Baseline plasma bicarbonate, mmol/L	−0.07 (−0.28 to 0.14)	0.50	0.08 (−0.09 to 0.25)	0.35
Baseline Ln plasma aldosterone, ng/L	−0.2 (−1.0 to 0.7)	0.68	0.01 (−0.63 to 0.65)	0.97
Baseline Ln plasma renin, ng/L	−0.5 (−1.1 to 0.1)	0.13	0.14 (−0.29 to 0.56)	0.50

CI, confidence interval; RBC K⁺, red blood cell potassium; BMI, body mass index.